Back to Guavy Wire

Stocks

Merck Raises Revenue Guidance as Diversified Pipeline Takes Center Stage

Guavy AI Editorial Team Published August 13, 2026

Instruments

MRK

Merck's Q2 sales beat expectations, and the company raised its revenue guidance for 2026.

The new projections reflect management's confidence in the company's diversified pipeline and product launches.

Analysts are debating whether Merck can offset KEYTRUDA's loss of exclusivity with newer franchises like vaccines and cardiometabolic drugs.

The broadening portfolio includes updates on ENFLONSIA, LIPFENDRA, and oncology additions, creating multiple levers for growth.

More on Stocks

Stocks just now

US Tech Companies Deliver Mixed Bag as Cisco Beats Estimates

Stocks just now

Cisco Earnings Surge on Strong Networking Demand

Stocks just now

Cisco Bets on On-Premise AI Infrastructure as Enterprise Adoption Shifts

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy